Secondary Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?

Covino, Jean, DHSc, MPA, PA-C; Hoffman, Jennifer, MS, PA-C

Journal of the American Academy of PAs: March 2018 - Volume 31 - Issue 3 - p 12–14
doi: 10.1097/01.JAA.0000530303.23280.6c
Pharmacology Consult

ABSTRACT New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.

At Pace University-Lenox Hill Hospital in New York City, Jean Covino is a professor and Jennifer Hoffman is an associate professor in the PA program. Dr. Covino also practices at Medemerge Family Practice Center in Green Brook, N.J. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2018 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website